Hostname: page-component-745bb68f8f-cphqk Total loading time: 0 Render date: 2025-01-22T10:45:46.372Z Has data issue: false hasContentIssue false
  • English
  • Français

Teicoplanin- A New Agent for Gram-Positive Bacterial Infections

Published online by Cambridge University Press:  21 June 2016

Mark Eggleston  and
Joseph Ofosu
Mark Eggleston*
Affiliation:
Howard University, College of Pharmacy and Pharmacal Sciences, Washington, DC
Joseph Ofosu
Affiliation:
Howard University, College of Pharmacy and Pharmacal Sciences, Washington, DC
*
PO Box 115, Woodbridge, VA 22191
Get access Rights & Permissions [Opens in a new window]

Extract

Gram-positive bacterial infections remain a serious challenge for infectious disease practitioners. Many gram-positive organisms are developing new methods of antibiotic resistance, thus rendering our standard antimicrobial agents ineffective. Penicillin G resistance, methicillin-resistant Staphylococcus aureus and recently, a laboratory strain of vancomycin-resistant S aureus have become catalysts in the search for effective alternatives in the treatment of gram-positive bacterial infections. This review will briefly describe an investigational agent (investigational in the US, although used widely overseas) that has been very successful in treating gram-positive bacterial infections. The antibiotic, named teicoplanin. (Merrell-Dow Pharmaceuticals) may be approved for release in the United States in the future.

Originally known as teichomycin A, teicoplanin is a glycopeptide antibiotic, chemically similar to the vancomycin-ristocetin antibiotic group. Teicoplanin was discovered following the fermentation process of Actinoplanes teichomyceticus The antibiotic has a linear heptapeptide structure and weighs approximately 2000 daltons.

Type
Special Sections
Information
Infection Control & Hospital Epidemiology , Volume 9 , Issue 5 , May 1988 , pp. 209 - 211
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1988

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Williams, AH, Gruneberg, RN: Teicoplanin. J Antimicrob Chemother 1984; 14:441–448.Google ScholarPubMed
2. Bardone, MR, Paternoster, M, Coronelli, C: Teichomycins, new antibiotics from Actinoplanes Teichomyceticus nov. spp. II. Extraction and chemical characterization. J Antibiot 1978; 31:170–171.CrossRefGoogle Scholar
3. Parenti, F: Structure and mechanism of action of teicoplanin. J Hasp Infect 1986; 7(suppl A):79–83.CrossRefGoogle ScholarPubMed
4. Bardone, MR, Tuan, G, Coronelli, C: Preliminary structural studies on Teichomycin A2: A new antibiotic, in Marenkov, N, Ognyanov, I, Orahovats, A (eds): Proceedings of the 11th IUPAC International Symposium on the Chemistry of the Natural Product. Golden Sands, Bulgaria, 09 1978; 1:239–241.Google Scholar
5. Somma, S, Gastaldo, L: Mechanism of action of Teichomycin A2: A new antibiotic, in Periti, P. Gialdroni, GG (cds): Current Chemotherapy and Immunotherapy, Proceedings of the 12th International Congress of Chemotherapy. Florence, Italy, 07 1981; 1:343–345.Google Scholar
6. McNulty, CAM, Garden, GMF, Wise, R, et al: The pharmacokinetics and tissue penetration of teicoplanin, J Antimicrob Chemother 1985; 16:743–749.CrossRefGoogle ScholarPubMed
7. Wise, R, Donovan, IA, McNulty, CAM, et al: Teicoplanin, its pharmacokinetics, blister and peritoneal fluid penetration. J Hosp Infect 1986; 7(suppl A): 47–55.CrossRefGoogle ScholarPubMed
8. Lagast, H, Dodion, P, Klastersky, J: Comparison of pharmacokinetics and bactericidal activity of teicoplanin and vancomycin. J Antimicrob Chemother 1986; 18:513–520.CrossRefGoogle ScholarPubMed
9. Verbist, L, Tjandramaga, B. Hendrickx, B, et al: In vitro activity and human pharmacokinetics of teicoplanin. Antimicrob Agents Chemother 1984; 6:881–886.CrossRefGoogle Scholar
10. Traina, GL, Bonati, M: Pharmacokinetics of teicoplanin in man after intravenous administration. J Pharmacokinet Biopharm 1984; 12:119–128.CrossRefGoogle ScholarPubMed
11. Kucers, A, Bennett, NM: Vancomycin, in Kucers, A, Bennett, M (eds): The Use of Antibiotics, ed 3. London, William Heineman Medical Books Ltd, 1979, pp 646–654.Google Scholar
12. Bauernfeind, A: Teichomycin and AM-715 activity on staphylococci entero-cocci in comparsion to other antibiotic agents (abstract). Program and Abstracts of the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Chicago, 11 1981.Google Scholar
13. Berti, M, Pallanza, R, Arioli, V: Teichomycin A2: A new antibiotic from Actinoplanes. Activity in vitro and in vivo, in Periti, P, Gialdroni, GG (eds): Current Chemotherapy and Immunotherafry. Proceedings of the 12th international Congress of Chemotherapy, Florence, Italy, 07 1982; 1:343–345.Google Scholar
14. Cynamon, MM, Granato, PA: Comparison of the in vitro activities of teichomycin A2 and vancomycin against staphylococci and enterococci. Anti microb Agents Chemother 1982; 21:504–505.CrossRefGoogle ScholarPubMed
15. Fainstein, V, LeBlanc, B, Bodey, GP: Comparative in vitro study of teichomycin A2. Antimicrob Agents Chemother 1983; 23:497–499.CrossRefGoogle ScholarPubMed
16. Fainstein, V, Weaver, S, Bodey, GP: Comparative in vitro activity of teichomycin A2 against gram-positive cocci (abstract). Program and Abstracts of the 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Miami. 10 1982.Google Scholar
17. Fietta, A, Mangiarotti, P, Gialdroni, GG: In vitro activity of teichomycin A2 against clinical isolates of gram-positive bacteria, in Bertelli, A (ed): Future Trends in Chemotherapy, Proceedings of International Symposium, Tirrenia, Italy; Geneva, Bioscience Ediprint, 1982; 5:425–434.Google Scholar
18. Gruneberg, RN, Ridgway, GL, Cremer, AWF. et al: The sensitivity of gram-positive pathogens to teichomycin and vancomycin. Drugs Exp Clin Res 1983; 9:139–141.Google Scholar
19. Neu, HC. Saha, G, Labthavikul, P: The antibacterial activity of teichomycin against gram-positive species compared with other antibiotics (abstract). Programs and Abstracts of the 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Miami, 10 1982.Google Scholar
20. Pallanza, R. Berti, M. Goldstein, BP. et al: Teichomycin: In vitro and in vivo evaluation in comparison to other antibiotics. J Antimicrob Chemother 1983; 11:419–425.CrossRefGoogle ScholarPubMed
21. Berti, M, Pallanza, R. Arioli, V: In vitro and in vivo activity of teicoplanin against multiply resistant staphylococci. Fifth International Symposium on Antibiotic Resistance and R-plasmids. Castle Smolenice, Czechoslovakia, 09 1983.Google Scholar
22. Glupcyznski, Y, Labbe, M, Orokaert, F, et al: In vitro activity of teicoplanin and vancomycin against anaerobes. Eur J Clin Microbiol 1984; 3:50–51.CrossRefGoogle Scholar
23. Jadeja, L, Fainstein, V, LeBlanc, B, et al: Comparative in vitro activities of teichomycin and other antibiotics against JK diptheroids. Antimicrob Agents Chemother 1983; 24:145–146.CrossRefGoogle Scholar
24. Neu, HC, Labthavikul, P: In vitro activity of teichomycin compared with those of other antibiotics. Antimicrob Agents Chemother 1983; 24:425–428.CrossRefGoogle ScholarPubMed
25. Chen, HY, Williams, JD: The influence of gentamicin and ampicillin on the in vitro activity of vancomycin and teichomycin A2 against Streptococcus faecalis , in Spitzy, K, Karrer, K (eds): Proceedings of the 13th International Congress of Chemotherapy. Vienna, 1983, pp 33–35.Google Scholar
26. Farber, BB: Vancomycin: Renewed interest in an old drug (editorial). Eur J Clin Micobiol 1984; 3:1–3.CrossRefGoogle Scholar
27. Investigator's Handbook. Merrel-Dow Pharmaceuticals Ltd, 1984.Google Scholar
28. Chambers, HF, Rusnak, NG, Hackbarth, CJ, et al: Treatment of Staphylococcus aureus endocarditis in rabbits with teichomycin (abstract). Program and A bstracts of the 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Las Vegas, 10 1983.Google Scholar
29. Brumfitt, W, Baillod, R, Smith, GW, et al: Teicoplanin for patients undergoing dialysis: Microbiological and pharmacokinetic aspects. Proceedings of the 14th International Congress of Chemotherapy. Kyoto, Japan, 06 1985; 27–29.Google Scholar